REC604c

REC604c is a novel adjuvanted recombinant 9-valent human papillomavirus (HPV) vaccine being developed by Jiangsu Rec-Biotechnology. It is designed to protect against HPV infections that cause cervical cancer and genital warts (condyloma acuminatum). The vaccine utilizes a proprietary novel adjuvant system combined with recombinant protein technology, which is intended to enhance immunogenicity and allow for a two-dose regimen. REC604c is specifically being developed for the male population and upgraded markets. Preclinical studies have shown that two doses of REC604c demonstrate immunogenicity generally superior to three doses of the standard 9-valent HPV vaccine.